Depemokimab, our new long-acting anti-IL ... Blenrep and have a better understanding of how to mitigate eye-related side effects. Around a third of patients in Blenrep studies have reported ...

Depemokimab is a monoclonal antibody targeting ... GSK's vaccine Arexvy must include warnings about a rare neurological side effect, Guillain-Barré syndrome. Meanwhile, the company's ...

Depemokimab is a monoclonal antibody targeting interleukin ... The FDA has directed that GSK's vaccine Arexvy must include warnings about a rare neurological side effect, Guillain-Barré syndrome.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...